Median's share price rose sharply on Wednesday morning on the Paris stock exchange, following the award of a contract by one of the world's "top 3" pharmaceutical companies.

The company reports that it has been selected as preferred supplier of imaging services for clinical trials, following an in-depth process.

As part of the agreement, Median will be responsible for managing centralized image readouts for late-stage trials of its client's unnamed pipeline of oncology drugs.

In a press release, Median points out that it is now the preferred supplier of two of the world's three largest pharmaceutical companies, in terms of oncology revenues.

The amount of the contract was not disclosed.

At around 10:40 a.m., the share price was up 5%, after having jumped more than 13% at the opening.

Copyright (c) 2024 CercleFinance.com. All rights reserved.